Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.95 |
| ▸ | BAD | Q92934 | 1/20 | 0.95 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352072 | 0.98 | BCL2L1 (1.00) | BCL2L1BADDRD2DRD3TSHR | |
| SCHEMBL150894 | 0.98 | BCL2L1 (1.00) | BCL2L1BADDRD2DRD3TSHR | |
| SCHEMBL152396 | 0.95 | BCL2L1 (0.95) | BCL2L1BADDRD2DRD3TSHR | |
| SCHEMBL27700160 | 0.95 | BCL2L1 (0.95) | BCL2L1BADDRD2DRD3TSHR | |
| SCHEMBL150001 | 0.95 | BCL2L1 (0.95) | BCL2L1BADDRD2DRD3TSHR | |
| SCHEMBL29442708 | 0.93 | BCL2L1 (0.91) | BCL2L1BADDRD2DRD3TSHR | |
| SCHEMBL154077 | 0.93 | BCL2L1 (0.91) | BCL2L1BADDRD2DRD3TSHR | |
| SCHEMBL150017 | 0.83 | — | — | |
| SCHEMBL29414699 | 0.83 | — | — | |
| SCHEMBL11189689 | 0.83 | BCL2L1 (0.72) | BCL2L1BADDRD2DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103906514-A | Compositions and methods for treating metabolic disorders | BIOMED VALLEY DISCOVERIES INC | 2014-07-02 | — | — | CN | claimed |
| CN-1929829-B | (S) -2-N-propylamino-5-hydroxytetraline as D3 agonist | SANOL ARZNEI SCHWARZ GMBH | 2010-12-15 | — | — | CN | claimed |
| CN-1929829-A | (S) -2-N-propylamino-5-hydroxytetraline as D3 agonist | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-03-14 | — | — | CN | claimed |
| CN-103906514-A | Compositions and methods for treating metabolic disorders | BIOMED VALLEY DISCOVERIES INC | 2014-07-02 | — | — | CN | disclosed |
| CN-1929829-B | (S) -2-N-propylamino-5-hydroxytetraline as D3 agonist | SANOL ARZNEI SCHWARZ GMBH | 2010-12-15 | — | — | CN | disclosed |
| CN-1897935-B | Use of rotigotine for treatment or prevention of dopaminergic neurone loss | SANOL ARZNEI SCHWARZ GMBH | 2010-05-26 | — | — | CN | disclosed |
| CN-101686937-A | What be used to prevent and/or treat the unpeaceful disease of limbs can be via the pharmaceutical composition of the pharyngeal dopamine agonist of sending of mouth and nose | SANOL ARZNEI SCHWARZ GMBH | 2010-03-31 | — | — | CN | disclosed |
| CN-1929829-A | (S) -2-N-propylamino-5-hydroxytetraline as D3 agonist | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-03-14 | — | — | CN | disclosed |
| CN-1897935-A | Use of rotigotine for treatment or prevention of dopaminergic neurone loss | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-01-17 | — | — | CN | disclosed |